Evidence map›Paper›PMID 27003495›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2016

FOXP3+Helios+ Regulatory T Cells, Immune Activation, and Advancing Disease in HIV-Infected Children.

Alka Khaitan, Adam Kravietz, Mussa Mwamzuka, Fatma Marshed, Tiina Ilmet, Swalehe Said, Aabid Ahmed, William Borkowsky, Derya Unutmaz

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Coexpression of Helios in Foxp3Disease markers · 2021
    Review
  6. Review
  7. Article
  8. Foxp3BMC immunology · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Functional Interrogation of Primary Human T Cells via CRISPR Genetic Editing.Journal of immunology (Baltimore, Md. : 1950) · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. TIGIT and Helios Are Highly Expressed on CD4The Journal of investigative dermatology · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alka Khaitan*New York University School of Medicine, New York, NY; †Division of Infectious Diseases and Immunology, Department of Pediatrics, New York University School of Medicine, New York, NY; ‡Department of Microbiology, New York University School of Medicine, New York, NY; §Comprehensive Care Centre, Bomu Hospital, Mombasa, Kenya; ‖Department of Pathology, New York University School of Medicine, New York, NY; ¶Department of Medicine, New York University School of Medicine, New York, NY; and #Currently, The Jackson Laboratory for Genomic Medicine, Farmington, CT.
Adam Kravietz
Mussa Mwamzuka
Fatma Marshed
Tiina Ilmet
Swalehe Said
Aabid Ahmed
William Borkowsky
Derya Unutmaz
New York University · US

Funding

Immunobiology of Regulatory T Cells in HIV InfectionR01AI065303 · NIAID · VANDERBILT UNIVERSITY · PI UNUTMAZ, DERYA · 2005 to 2015
$4.3M
Mechanisms and Consequences of Immune Activation in HIV Infected ChildrenK08AI093235 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KHAITAN, ALKA · 2011 to 2016
$778k
NIAID NIH HHS K08 AI093235NIAID NIH HHS R01 AI065303
6 · The paper itself

Abstract

Regulatory T cells (Tregs) are functionally suppressive CD4 T cells, critical for establishing peripheral tolerance and controlling inflammatory responses. Previous reports of Tregs during chronic HIV disease have conflicting results with higher or lower levels compared with controls. Identifying true Tregs with suppressive activity proves challenging during HIV infection, as traditional Treg markers, CD25 and FOXP3, may transiently upregulate expression as a result of immune activation (IA). Helios is an Ikaros family transcription factor that marks natural Tregs with suppressive activity and does not upregulate expression after activation. Coexpression of FOXP3 and Helios has been suggested as a highly specific marker of "bona fide" Tregs. We evaluated Treg subsets by FOXP3 coexpressed with either CD25 or Helios and their association with HIV disease progression in perinatally infected HIV-positive children. Identifying Tregs by FOXP3 coexpression with Helios rather than CD25 revealed markedly higher Treg frequencies, particularly in HIV+ children. Regardless of antiretroviral therapy, HIV-infected children had a selective expansion of memory FOXP3+Helios+ Tregs. The rise in memory Tregs correlated with declining HIV clinical status, indicated by falling CD4 percentages and CD4:CD8 ratios and increasing HIV plasma viremia and IA. In addition, untreated HIV+ children exhibited an imbalance between the levels of Tregs and activated T cells. Finally, memory Tregs expressed IA markers CD38 and Ki67 and exhaustion marker, PD-1, that tightly correlated with a similar phenotype in memory CD4 T cells. Overall, HIV-infected children had significant disruptions of memory Tregs that associated with advancing HIV disease.

Indexed as

Disease ProgressionLymphocyte ActivationADP-ribosyl Cyclase 1Anti-HIV AgentsCD4-Positive T-LymphocytesChildFlow CytometryForkhead Transcription FactorsHIV-1HIV InfectionsHumansIkaros Transcription FactorImmunologic MemoryInflammationInterleukin-2 Receptor alpha SubunitKi-67 AntigenADP-ribosyl Cyclase 1Anti-HIV AgentsForkhead Transcription FactorsFOXP3 protein, humanIkaros Transcription FactorIKZF2 protein, humanInterleukin-2 Receptor alpha SubunitKi-67 AntigenPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Identifiers

PMID27003495
PMCPMC4942350
OpenAlexW2328122128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.